



ASX ANNOUNCEMENT

14 March 2024

FUNDING COMMITMENT AGREEMENT UPDATE

CARDIEX Limited (ASX:CDX) (**CARDIEX**, the **Company**) provides an update on the Funding Commitment Agreement (**FCA**) with C2 Ventures Pty Limited (**C2V**, owned by Directors Niall Cairns and Craig Cooper) as announced on 8 November 2023.

The Company and C2V have entered into a variation of the FCA by increasing the facility limit by \$966,434.40 which brings the total facility limit to \$8,466,434.40 (with \$6,000,000 remaining undrawn), and replacing \$7,500,000 as previously announced. This variation and increased investment from C2V, which in effect increases the FCA facility limit by the amount of the C2V underwriting of the Entitlement Offer, ensures that CARDIEX completes the previously announced \$14 million fund-raising package.

Shareholder approval will be sought at an upcoming Extraordinary General Meeting of Shareholders, to the extent possible, for the potential conversion to equity on the same pricing and other terms as the recent capital raising of all loans under the FCA, up to the maximum facility limit.

All other key terms of the FCA remain unchanged.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CARDIEX

CARDIEX focuses on increasing longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CARDIEX is listed on the Australian Stock Exchange ("CDX").